Tests survodutide in adults with liver scarring from fatty liver disease
Tests survodutide, a weekly injection, in adults with MASH cirrhosis.
Key facts
- Who runs it
- Boehringer Ingelheim
- Where
- Arlington, Atlanta, Austin, Bastrop, Bellaire, Bradenton, Brandon, Bristol, Brooklyn, Brooksville, Brownsville, Canoga Park, Chandler, Chattanooga, Chula Vista, Clarksville, Clinton Township, Colorado Springs, Columbia, Columbus, Coral Gables, Coronado, Cutler Bay, Dallas, Denison, Englewood, Fayetteville, Flourtown, Fort Myers, Fountain Valley, Garden City, Garland, Georgetown, Greenville, Hammond, Hershey, Hialeah, Hialeah Gardens, Homestead, Houston, Huntington Park, Inglewood, Kansas City, La Mesa, Lady Lake, Lancaster, Las Vegas, Laurelton, Lewisville, Macon, Mansfield, Marrero, McAllen, Mentor, Miami, Miami Lakes, Minneapolis, Montclair, Nashville, New Port Richey, New York, Omaha, Orange, Orlando, Oxnard, Palmetto Bay, Pembroke Pines, Peoria, Poway, Raleigh, Rialto, Richmond, Riverdale, Riverview, Rochester, San Antonio, San Bernardino, San Diego, Scottsdale, Seattle, Shreveport, South Bend, Spokane, Springboro, St. Petersburg, Summerville, Tampa, The Villages, Tucson, Tulsa, University Park, Waco, Warren Township, West Des Moines, Westlake, Wichita Falls, Winter Park, Wyoming, Wyomissing, and Zephyrhills, United StatesSee the 127 sitesAlso in 36 other countries, 329 sites
- Trial code
- NCT06632457
- EU 2024-513741-36-00
- U1111-1307-0227
- Registry title
- LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,590 people, planned
- Started
- 12 Nov 2024
- Expected to end
- 5 Jun 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Survodutide
- Placebo matching survodutide
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a liver disease called MASH (also called NASH) who have compensated cirrhosis and a higher body weight. It tests the weekly injection survodutide against placebo.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Compensated MASH (NASH) cirrhosis, meaning cirrhosis without complications of the liver failing; liver fat shown by MRI-PDFF or FibroScan unless a recent liver biopsy shows fatty liver disease
- Earlier treatment
- Not stated
- Biomarker or test result
- BMI of 27 kg/m2 or more (25 kg/m2 or more for Asian participants)
Main reasons for not taking part
- Heavy alcohol use now or in the past 5 years
- Past or current liver decompensation: bleeding from portal hypertension, ascites or hepatic encephalopathy
- MELD score above 12 due to liver disease
- Other chronic liver diseases, or hepatitis B or hepatitis C
- Liver transplant or being on a transplant list; TIPS or other portal hypertension procedure
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Male or female adults ≥18 years of age at the time of screening, and at least the legal age of consent in countries where it is >18 years
- Body mass index (BMI) ≥27 kg/m2(≥25 kg/m2 for Asian trial participants)
- Compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis
- Magnetic resonance imaging proton density fat fraction (MRI-PDFF) fat fraction ≥5% or FibroScan® with controlled attenuation parameter (CAP) ≥288 dB/m, obtained during the screening period or a historic MRI-PDFF ≤12 weeks prior to randomisation (except for patients with 'cryptogenic cirrhosis' where MRI-PDFF <5% or FibroScan® with CAP <288 dB/m is allowed). This inclusion criterion does not apply for participants with a recent (≤12 months prior to randomisation) liver biopsy showing steatosis/steatohepatitis
- Further inclusion criteria apply
Who cannot take part
- Model of end-stage liver Disease (MELD) score >12 due to liver disease
- History or current (i.e. at screening) hepatic decompensation event of any of the following but not limited to:; Portal hypertension-related upper gastrointestinal (GI) bleeding; Ascites; Hepatic encephalopathy (HE) ≥Grade 1 according to the West Haven criteria
- History or evidence of other chronic liver diseases, such as primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis or overlap syndrome, Wilson's disease, alpha-1-antitrypsin deficiency, or genetic haemochromatosis
- Hepatitis B positive (defined as positive hepatitis B surface antigen (HBsAg)) or history of chronic HBV infection
- Hepatitis C positive (defined as positive hepatitis C virus (HCV) antibody and a positive HCV ribonucleic acid (RNA))
- Evidence of alcoholic liver disease, or drug-induced liver disease, as defined on the basis of typical exposure and history
- History of liver transplantation or listed for liver transplantation
- History of transjugular intrahepatic portosystemic shunt (TIPS) or other radiological/surgical procedure for portal hypertension treatment
- Any of the following lab test result at screening; Albumin below <3.5 g/dL (<35.0 g/L); International normalised ratio (INR) >1.3 unless due to therapeutic anticoagulants; Total bilirubin (TBL) >1.2x upper limit of normal (ULN) NOTE: Trial participants with Gilbert Syndrome are eligible with a TBL >1.2x ULN if reticulocyte count is within normal limits, haemoglobin is within normal limits unless due to chronic anaemia and unrelated to haemolysis, and direct bilirubin is <20% of TBL; Alkaline phosphatase >1.5x ULN; PLT <100,000/µL (<100 GI/L)
- Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >5x ULN
- Current or history (<5 years) of significant alcohol consumption, defined as an average of >140 g/week in female patients and >210 g/week in male patients, for a period of >3 consecutive months, or an inability to reliably quantify alcohol consumption based upon judgment of the investigator
- Further exclusion criteria apply
Where in United States
Also in 36 other countries, 329 sites
- Texas Clinical Research Institute, LLCArlington, United StatesContact: Boehringer IngelheimTaking people
- Piedmont HospitalAtlanta, United StatesContact: Boehringer IngelheimTaking people
- American Research Corporation - AustinAustin, United StatesContact: Boehringer IngelheimTaking people
- IMA Clinical Research AustinAustin, United StatesContact: Boehringer IngelheimTaking people
- Pinnacle Clinical Research - AustinAustin, United StatesContact: Boehringer IngelheimTaking people
- Velocity Clinical Research AustinAustin, United StatesContact: Boehringer IngelheimTaking people
- Delta Research Partners, LLCBastrop, United StatesContact: Boehringer IngelheimTaking people
- Pinnacle Clinical Research, LLCBellaire, United StatesContact: Boehringer IngelheimTaking people
- Synergy HealthcareBradenton, United StatesContact: Boehringer IngelheimTaking people
- Synergy Healthcare of TampaBrandon, United StatesContact: Boehringer IngelheimTaking people
- Connecticut Gastroenterology Clinical Research FoundationBristol, United StatesContact: Boehringer IngelheimTaking people
- NewYork-Presbyterian Brooklyn Methodist HospitalBrooklyn, United StatesContact: Boehringer IngelheimTaking people
- Access Research InstituteBrooksville, United StatesContact: Boehringer IngelheimTaking people
- South Texas Research Institute - BrownsvilleBrownsville, United StatesContact: Boehringer IngelheimTaking people
- Hope Clinical ResearchCanoga Park, United StatesContact: Boehringer IngelheimTaking people
- Arizona Liver Health - Chandler ClinicChandler, United StatesContact: Boehringer IngelheimTaking people
- ClinSearch LLCChattanooga, United StatesContact: Boehringer IngelheimTaking people
- Velocity Clinical Research, Chula VistaChula Vista, United StatesContact: Boehringer IngelheimTaking people
- Innovative Clinical ResearchClarksville, United StatesContact: Boehringer IngelheimTaking people
- Clinical Research Institute of Michigan, LLCClinton Township, United StatesContact: Boehringer IngelheimTaking people
- Future Innovative TreatmentsColorado Springs, United StatesContact: Boehringer IngelheimTaking people
- ObjectiveHealth-Columbia Digestive Health ResearchColumbia, United StatesContact: Boehringer IngelheimTaking people
- ObjectiveHealth-GI Associates ResearchColumbia, United StatesContact: Boehringer IngelheimTaking people
- The Ohio State University -Wexner Medical CenterColumbus, United StatesContact: Boehringer IngelheimTaking people
- Hi Tech and Global Research, LLCCoral Gables, United StatesContact: Boehringer IngelheimTaking people
- Southern California Research CenterCoronado, United StatesContact: Boehringer IngelheimTaking people
- Cenara Clinical ResearchCutler Bay, United StatesContact: Boehringer IngelheimTaking people
- Dallas Research InstituteDallas, United StatesContact: Boehringer IngelheimTaking people
- GI Alliance Research - DallasDallas, United StatesContact: Boehringer IngelheimTaking people
- Zenos Clinical ResearchDallas, United StatesContact: Boehringer IngelheimTaking people
- Soma Clinical TrialsDenison, United StatesContact: Boehringer IngelheimTaking people
- South Denver Gastroenterology PCEnglewood, United StatesContact: Boehringer IngelheimTaking people
- Coastal Research Institute, LLCFayetteville, United StatesContact: Boehringer IngelheimTaking people
- US Digestive HealthFlourtown, United StatesContact: Boehringer IngelheimTaking people
- Covenant Metabolic Specialists, LLC - Fort MyersFort Myers, United StatesContact: Boehringer IngelheimTaking people
- Ark Clinical ResearchFountain Valley, United StatesContact: Boehringer IngelheimTaking people
- EmVenio Research Center at Prime Healthcare - Farmers BranchGarden City, United StatesContact: Boehringer IngelheimTaking people
- DHAT Reseach InstituteGarland, United StatesContact: Boehringer IngelheimTaking people
- Pinnacle Clinical Research, LLCGeorgetown, United StatesContact: Boehringer IngelheimTaking people
- Carolina ResearcheGreenville, United StatesContact: Boehringer IngelheimTaking people
- ASHA Clinical Research-Munster, LLCHammond, United StatesContact: Boehringer IngelheimTaking people
- Penn State Milton S. Hershey Medical CenterHershey, United StatesContact: Boehringer IngelheimTaking people
- NeoClinical ResearchHialeah, United StatesContact: Boehringer IngelheimTaking people
- Evolution Clinical TrialsHialeah Gardens, United StatesContact: Boehringer IngelheimTaking people
- Global Research AssociatesHomestead, United StatesContact: Boehringer IngelheimTaking people
- Ben Taub General HospitalHouston, United StatesContact: Boehringer IngelheimTaking people
- Biopharma Informatic, Inc. Research CenterHouston, United StatesContact: Boehringer IngelheimTaking people
- Research Physicians NetworkHouston, United StatesContact: Boehringer IngelheimTaking people
- Velocity Clinical Research-Huntington ParkHuntington Park, United StatesContact: Boehringer IngelheimTaking people
- 310 Clinical ResearchInglewood, United StatesContact: Boehringer IngelheimTaking people
- Kansas City Research InstituteKansas City, United StatesContact: Boehringer IngelheimTaking people
- Velocity Clinical Research, San DiegoLa Mesa, United StatesContact: Boehringer IngelheimTaking people
- Lake Center for Clinical ResearchLady Lake, United StatesContact: Boehringer IngelheimTaking people
- Om Research LLCLancaster, United StatesContact: Boehringer IngelheimTaking people
- US Digestive HealthLancaster, United StatesContact: Boehringer IngelheimTaking people
- Clinical Research of South NevadaLas Vegas, United StatesContact: Boehringer IngelheimTaking people
- Excel Clinical ResearchLas Vegas, United StatesContact: Boehringer IngelheimTaking people
- Jubilee Clinical Research, Inc.Las Vegas, United StatesContact: Boehringer IngelheimTaking people
- Basil ClinicalLaurelton, United StatesContact: Boehringer IngelheimTaking people
- Epic Clinical ResearchLewisville, United StatesContact: Boehringer IngelheimTaking people
- Gastroenterology Associates of Central GeorgiaMacon, United StatesContact: Boehringer IngelheimTaking people
- GI Alliance Research - MansfieldMansfield, United StatesContact: Boehringer IngelheimTaking people
- Tandem Clinical ResearchMarrero, United StatesContact: Boehringer IngelheimTaking people
- Biopharma Informatic, LLCMcAllen, United StatesContact: Boehringer IngelheimTaking people
- Centex Studies, Inc.McAllen, United StatesContact: Boehringer IngelheimTaking people
- Great Lakes GastroenterologyMentor, United StatesContact: Boehringer IngelheimTaking people
- BioMed Research & Medical CenterMiami, United StatesContact: Boehringer IngelheimTaking people
- ECIR Miami Holdings LLC dba IMICMiami, United StatesContact: Boehringer IngelheimTaking people
- Entrust Clinical ResearchMiami, United StatesContact: Boehringer IngelheimTaking people
- MplusM - Century ResearchMiami, United StatesContact: Boehringer IngelheimTaking people
- Optimus U Corporation-Miami-69452Miami, United StatesContact: Boehringer IngelheimTaking people
- Research Associates of South Florida, LLCMiami, United StatesContact: Boehringer IngelheimTaking people
- Schiff Center Liver DiseasesMiami, United StatesContact: Boehringer IngelheimTaking people
- Floridian Clinical ResearchMiami Lakes, United StatesContact: Boehringer IngelheimTaking people
- MNGI Digestive Health, PAMinneapolis, United StatesContact: Boehringer IngelheimTaking people
- Catalina Research Institute, LLCMontclair, United StatesContact: Boehringer IngelheimTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Boehringer IngelheimTaking people
- Advanced Research InstituteNew Port Richey, United StatesContact: Boehringer IngelheimTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Boehringer IngelheimNot yet recruiting
- University of Nebraska Medical CenterOmaha, United StatesContact: Boehringer IngelheimTaking people
- Clinnova Research SolutionsOrange, United StatesContact: Boehringer IngelheimTaking people
- Charter ResearchOrlando, United StatesContact: Boehringer IngelheimTaking people
- Endoscopic Research, IncOrlando, United StatesContact: Boehringer IngelheimTaking people
- OMEGA Research GroupOrlando, United StatesContact: Boehringer IngelheimTaking people
- Fomat Medical ResearchOxnard, United StatesContact: Boehringer IngelheimTaking people
- Innovation Medical Research CenterPalmetto Bay, United StatesContact: Boehringer IngelheimTaking people
- MplusM - Best Choice Medical and Research ServicePembroke Pines, United StatesContact: Boehringer IngelheimTaking people
- The Institute for Liver Health II DBA Arizona Clinical TrialsPeoria, United StatesContact: Boehringer IngelheimTaking people
- Cadena Care Institute, LLCPoway, United StatesContact: Boehringer IngelheimTaking people
- Ficramed Research InstitutePoway, United StatesContact: Boehringer IngelheimTaking people
- M3 Wake Research, Inc.Raleigh, United StatesContact: Boehringer IngelheimTaking people
- Inland Empire Clinical Trials, LLCRialto, United StatesContact: Boehringer IngelheimTaking people
- GI Select Health Research, LLCRichmond, United StatesContact: Boehringer IngelheimTaking people
- VCU Medical Center West HospitalRichmond, United StatesContact: Boehringer IngelheimNot yet recruiting
- EmVenio Research Center at Prime Healthcare - RiverdaleRiverdale, United StatesContact: Boehringer IngelheimTaking people
- Covenant Metabolic Specialist, LLC - RiverviewRiverview, United StatesContact: Boehringer IngelheimTaking people
- University of Rochester Medical CenterRochester, United StatesContact: Boehringer IngelheimTaking people
- American Research Corporation at the Texas Liver InstituteSan Antonio, United StatesContact: Boehringer IngelheimTaking people
- Brooke Army Medical CenterSan Antonio, United StatesContact: Boehringer IngelheimTaking people
- HASresearchSan Antonio, United StatesContact: Boehringer IngelheimTaking people
- Metro Clinical TrialsSan Bernardino, United StatesContact: Boehringer IngelheimTaking people
- Acclaim Clinical ResearchSan Diego, United StatesContact: Boehringer IngelheimTaking people
- Scottsdale Medical Specialists, LtdScottsdale, United StatesContact: Boehringer IngelheimTaking people
- Velocity Clinical Research, SeattleSeattle, United StatesContact: Boehringer IngelheimTaking people
- Louisiana Research Center, LLCShreveport, United StatesContact: Boehringer IngelheimTaking people
- Digestive Research Alliance of MichianaSouth Bend, United StatesContact: Boehringer IngelheimTaking people
- Velocity Clinical Research-Spokane-69716Spokane, United StatesContact: Boehringer IngelheimTaking people
- ObjectiveHealth-DSI Research - Springboro, LLCSpringboro, United StatesContact: Boehringer IngelheimTaking people
- Global Clinical ProfessionalsSt. Petersburg, United StatesContact: Boehringer IngelheimTaking people
- Palmetto Clinical ResearchSummerville, United StatesContact: Boehringer IngelheimTaking people
- International Center for ResearchTampa, United StatesContact: Boehringer IngelheimTaking people
- Charter ResearchThe Villages, United StatesContact: Boehringer IngelheimTaking people
- Adobe Clinical Research LLCTucson, United StatesContact: Boehringer IngelheimTaking people
- Arizona Liver Health - TucsonTucson, United StatesContact: Boehringer IngelheimTaking people
- Del Sol Research Management, LLCTucson, United StatesContact: Boehringer IngelheimTaking people
- Options Health ResearchTulsa, United StatesContact: Boehringer IngelheimTaking people
- Covenant Metabolic Specialists, LLC - University ParkUniversity Park, United StatesContact: Boehringer IngelheimTaking people
- Objective Health-Digestive Research of Central TexasWaco, United StatesContact: Boehringer IngelheimTaking people
- Velocity Clinical Research, WacoWaco, United StatesContact: Boehringer IngelheimTaking people
- IMA Clinical Research-Warren-69742Warren Township, United StatesContact: Boehringer IngelheimTaking people
- Iowa Diabetes and Endocrinology Research CenterWest Des Moines, United StatesContact: Boehringer IngelheimTaking people
- Northshore Gastroenterology ResearchWestlake, United StatesContact: Boehringer IngelheimTaking people
- ObjectiveHealth-Digestive Health Research of North TexasWichita Falls, United StatesContact: Boehringer IngelheimTaking people
- Conquest ResearchWinter Park, United StatesContact: Boehringer IngelheimTaking people
- West Michigan Clinical Research CenterWyoming, United StatesContact: Boehringer IngelheimTaking people
- US Digestive HealthWyomissing, United StatesContact: Boehringer IngelheimTaking people
- Florida Medical Clinic, P.A.Zephyrhills, United StatesContact: Boehringer IngelheimTaking people
About the trial
What the trial wants to find out
This study is open to adults who are at least 18 years old and have:
Read full original descriptionShow less
* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian.
People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function.
Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly.
Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study.
The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the liver parameters are measured using different imaging methods. The participants also fill in questionnaires about their symptoms. The results are compared between the groups to see whether the treatment works.
The 2 groups in the trial
- SurvodutideTreatment being tested
- PlaceboPlacebo, for comparison
Treatment: Placebo matching survodutide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis
- Plain-language title
- Tests survodutide in adults with liver scarring from fatty liver diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 November 2026